Neumora Therapeutics, Inc. Common Stock
NMRA
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -0.35 | -71.65% |
| 2025 | -1.23 | -82.19% |
| 2024 | -6.93 | -39.63% |
| 2023 | -11.48 | -39.15% |
| 2022 | -18.86 | 81.29% |
| 2021 | -10.40 | -58.17% |
| 2020 | -24.87 | 0.00% |
| 2019 | 0.00 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 34.39 | -9,963.32% |
US
|
|
| -31.59 | 8,960.54% |
US
|
|
| -25.99 | 7,352.05% |
AU
|
|
| 25.67 | -7,461.92% |
BE
|
|
| 45.52 | -13,153.57% |
NL
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.
Questions about Neumora Therapeutics, Inc. Common Stock's P/E ratio
What is Neumora Therapeutics, Inc. Common Stock's P/E ratio?
Neumora Therapeutics, Inc. Common Stock's P/E ratio is -0.35, as of Nov 2026.
What was Neumora Therapeutics, Inc. Common Stock's P/E ratio in 2025?
In 2025, Neumora Therapeutics, Inc. Common Stock's P/E ratio was -1.23, compared with -6.93 in 2024.
How has Neumora Therapeutics, Inc. Common Stock's P/E ratio changed since 2020?
From 2020 to 2025, Neumora Therapeutics, Inc. Common Stock's P/E ratio was highest in 2025 (-1.23) and lowest in 2020 (-24.87).
How does Neumora Therapeutics, Inc. Common Stock's P/E ratio compare with similar companies?
Neumora Therapeutics, Inc. Common Stock's P/E ratio (-0.35) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with 45.52.